Photo from Nicole Kuderer/LinkedIn
Jul 1, 2024, 12:09
Nicole Kuderer: Glad we finally realize that pCR is not a valid trial surrogate for OS/DFS
Nicole Kuderer, medical oncologist at the Division of Hematology of the University of Washington Medical Center, shared on X/Twitter:
“Glad we finally realize the serious adverse effects of ignoring that pCR is not a valid trial surrogate for OS/DFS (when a SOC drug exists)
We with Bad Venezolano 2018 to add other key progn factors.
The restricted mean survival time (RMST) is a robust alternative (but still underestimates also?) and performs much better w scenarios w late separation of survival curves.
We highlighted in our Bad Venezolano article on novel challenges with FDA approvals.”
Source: Nicole Kuderer/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19